One month after the groundbreaking ceremony of Park Innovaare’s new Innovation Campus, leadXpro is the first company to sign a tenancy agreement.
Posts by Stephan Müller:
In situ crystallography as an emerging method for structure solution of membrane proteins: the case of CCR2A
The in meso in situ serial X-ray crystallization method enables structure determination of very fragile crystals.
leadXpro CEO Michael Hennig contributes a chapter about the progress of structure biology in drug discovery
Lundbeck partners with leadXpro to discover drugs for membrane protein targets by high-resolution X-ray and cryo-Electron Microscopy
Astex Pharmaceuticals partners with leadXpro to facilitate structure-based drug discovery for membrane protein targets by cryo-Electron Microscopy
Crystal Structure of CC Chemokine Receptor 2A in Complex with an Orthosteric Antagonist Provides Insights for the Design of Selective Antagonists
Two independent structures of CCR2A in complex with the orthosteric antagonist MK-0812 were solved, confirming the importance of residue E2917.39 for antagonist binding. Structural modeling of pyrimidine amide antagonists showed an interaction with the non-conserved H1213.33, leading to a significant selectivity over CCR5, suggesting strategies for highly selective CCR2 antagonist design.
leadXpro and Sanofi collaborate for cryo-EM structure project
leadXpro determined the first protein structure at the Swiss Free Electron Laser (SwissFEL) facilities.